Inter Parfums posts preliminary Q2 numbers
This article was originally published in The Rose Sheet
Executive Summary
Inter Parfums announced July 23 that net sales for the second quarter of 2010 jumped to $107.8 million, a 21.6% increase from the same period last year. Fragrance brands leading the charge are Lanvin, with a 21% increase in sales, Burberry, up 26%, and Paul Smith, up 12%. New releases from Van Cleef & Arpels drove the brand's sales up 36%, while S.T. Dupont's two new entries, Intense and Essence Pure Ice, headed a 65% sales gain. By region, first-half sales rose 68% in Eastern Europe and 67% in South America. North America enjoyed a more modest increase of 14%, and Europe, 12%. Inter Parfums will release its final results for the second quarter Aug. 9. Earlier this month, the firm inked a licensing arrangement with designer Betsey Johnson to design, manufacture and sell fragrance, color cosmetics and other personal-care products thorough Betsey Johnson stores (1"The Rose Sheet" July 12, 2010, In Brief)
You may also be interested in...
Inter Parfums to partner with Betsey Johnson
New York-based firm has entered into a global agreement with fashion designer Betsey Johnson to design, manufacture and sell fragrance, color cosmetics and other personal-care products through Betsey Johnson stores, in addition to licensing products for sale at specialty stores, department stores and other retail outlets. Inter Parfums "envison[s] building an upscale fragrance and beauty enterprise around the qualities that have defined and redefined the Betsey Johnson label," President Andy Clarke states in July 9 release. First product launch is expected in August "with a new take on the designer's vintage fragrance," firm says
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.